Fas ligand expression in esophageal carc
β
Mamoun Younes; Mary R. Schwartz; Atilla Ertan; Delia Finnie; Anas Younes
π
Article
π
2000
π
John Wiley and Sons
π
English
β 178 KB
π 1 views
## BACKGROUND. Although esophageal adenocarcinomas (EADCA) have been shown to have substantially reduced or absent Fas expression, the status of Fas ligand (FasL) in these tumors, especially adenocarcinomas, is largely unknown. ## METHODS. Using immunohistochemistry, the authors investigated FasL